Does EDOXABAN Cause Interstitial lung disease? 95 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 95 reports of Interstitial lung disease have been filed in association with EDOXABAN (SAVAYSA). This represents 1.1% of all adverse event reports for EDOXABAN.
95
Reports of Interstitial lung disease with EDOXABAN
1.1%
of all EDOXABAN reports
34
Deaths
72
Hospitalizations
How Dangerous Is Interstitial lung disease From EDOXABAN?
Of the 95 reports, 34 (35.8%) resulted in death, 72 (75.8%) required hospitalization, and 10 (10.5%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for EDOXABAN.
What Other Side Effects Does EDOXABAN Cause?
Anaemia (663)
Cerebral infarction (419)
Gastrointestinal haemorrhage (378)
Renal impairment (359)
Cerebrovascular accident (337)
Dyspnoea (331)
General physical health deterioration (315)
Haematuria (312)
Fall (298)
Cardiac failure (272)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which EDOXABAN Alternatives Have Lower Interstitial lung disease Risk?
EDOXABAN vs EDOXABAN TOSILATE
EDOXABAN vs EFALIZUMAB
EDOXABAN vs EFANESOCTOCOG ALFA
EDOXABAN vs EFAVIRENZ
EDOXABAN vs EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL